A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Kardigan, Inc.
- Study ID
- NCT07771465
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Danicamtiv — DRUGDanicamtiv will be administered twice daily for up to 5 years
Study Details
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
Key Dates
- First listed
- Aug 18, 2026
- Start date
- Aug 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Nov 30, 2032
- Completion
- Jan 31, 2033
Study Design
- Enrollment
- 332 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Danicamtiv
Primary Outcome Measure
Frequency and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: 61 months ]
Central Contacts
- Kardigan Clinical Trial Information Team1-877-310-5135